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Cellular/Molecular
CRMP5 Interacts with Tubulin to Inhibit Neurite Outgrowth,
Thereby Modulating the Function of CRMP2
Se´bastien Brot,1 Ve´ronique Rogemond,2 Vale´rie Perrot,1 Naura Chounlamountri,1 Carole Auger,1 Je´roˆme Honnorat,1,2
andMahnaz Moradi-Ame´li1
1Inserm, Unite´ 842, Universite´ de Lyon, Lyon 1, Unite´ Mixte de Recherche S842, F-69372 Lyon Cedex 08, France, and 2Hospices Civils de Lyon, Neurologie
B, F-69677 Bron, France
Collapsin response mediator proteins (CRMPs) are involved in signaling of axon guidance and neurite outgrowth during neural devel-
opment and regeneration.Among these, CRMP2hasbeen identified as an important actor inneuronal polarity andaxonoutgrowth, these
activities being correlated with the reorganization of cytoskeletal proteins. In contrast, the function of CRMP5, expressed during brain
development, remains obscure.Here, we find that, in contrast to CRMP2, CRMP5 inhibits tubulin polymerization andneurite outgrowth.
Knockdown of CRMP5 expression by small interfering RNA confirms its inhibitory functions. CRMP5 forms a ternary complex with
MAP2 and tubulin, the latter involving residues 475-522 of CRMP5, exposed at the molecule surface. Using different truncated CRMP5
constructs, we demonstrate that inhibition of neurite outgrowth by CRMP5 is mediated by tubulin binding. When both CRMP5 and
CRMP2 are overexpressed, the inhibitory effect of CRMP5 abrogates neurite outgrowth promotion induced by CRMP2, suggesting that
CRMP5acts as a dominant signal. In culturedhippocampal neurons, CRMP5 showsno effect on axon growth,whereas it inhibits dendrite
outgrowth and formation, at an early developmental stage, correlated with its strong expression in neurites. At later stages, when
dendritesbegin to extend,CRMP5expression is absent.However,CRMP2 is constantly expressed.OverexpressionofCRMP5withCRMP2
inhibitsCRMP2-inducedoutgrowthbothon the axonal anddendritic levels.DeficiencyofCRMP5expression enhanced theCRMP2effect.
This antagonizing effect of CRMP5 is exerted through a tubulin-based mechanism. Thus, the CRMP5 binding to tubulin modulates
CRMP2 regulation of neurite outgrowth and neuronal polarity during brain development.
Introduction
Collapsin response mediator proteins (CRMPs) are cytosolic
phosphoproteins, highly expressed in the developing nervous
system. They act as signalingmolecules involved in the regulation
of microtubule polymerization, actin bundling, and endocytosis
leading to neuronal differentiation and axonal growth (Arimura
and Kaibuchi, 2007). Among CRMPs, CRMP2 was originally
identified as the signalingmolecule of the repulsive guidance cue,
semaphorin 3A, inducing growth cone collapse (Goshima et al.,
1995). CRMP2 has been reported to regulate neuronal polarity
and axon elongation (Yoshimura et al., 2005); its overexpression
inducesmultiple axon formation and primary axon elongation in
hippocampal neurons (Inagaki et al., 2001). CRMP2 modulates
axon growth through direct binding to tubulin and promoting
microtubule dynamics (Fukata et al., 2002). By binding to the
kinesin-1 light chain, CRMP2 regulates the transport of soluble
tubulin to the distal parts of growing axons, thereby modulating
axon growth (Kimura et al., 2005). Microtubule assembly can be
disrupted by CRMP2 phosphorylation (Yoshimura et al., 2005).
Some studies have suggested a role for CRMP2 in the etiology of
Alzheimer’s disease since hyperphosphorylation of CRMP2 may
interfere with tubulin assembly in neurites (Cole et al., 2004;
Uchida et al., 2005). In addition to its role in the transport of
soluble molecules, CRMP2 can act as a cargo receptor in the
transport of vesicles (Arimura et al., 2009).
Another member of the CRMP family, CRMP5, was indepen-
dently identified by different approaches (Fukada et al., 2000;
Inatome et al., 2000; Ricard et al., 2001). CRMP5 expression is
high in developing brain, but decreases in adult brain. Our group
has studied the spatiotemporal expression of CRMP5 in the cor-
tex, hippocampus, and cerebellum, and in postmitotic neuronal
precursors, suggesting a role in process extension (Ricard et al.,
2001). Other studies have reported the localization of CRMP5 at
the filopodia of growth cones, suggesting that it plays a role in
regulating filopodial dynamics and growth cone development
(Hotta et al., 2005). The association of CRMP5 with tyrosine
kinase Fes/Fps or mitochondrial septin has been previously re-
ported (Mitsui et al., 2002; Takahashi et al., 2003), although the
functional significance of these interactions has not been eluci-
dated. In addition to its expression during development, CRMP5
plays a role in neurological disorders. In adults, the reexpression
of CRMP5 causes paraneoplastic neurological syndromes, as a
result of cancer-induced autoimmune process. CRMP5 autoan-
tibodies were reported as markers of small-cell lung cancer and
thymoma (Ricard et al., 2001; Honnorat et al., 2009). Consider-
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ing the importance of CRMP5 in development and disease, it is
possible that it helps the remodeling of neuronal networks, al-
though, to date, its function is still poorly understood.
In the present study, we show that CRMP5 forms a ternary
complex with microtubule-associated protein 2 (MAP2) and tu-
bulin, resulting in the inhibition of neurite elongation. In hip-
pocampal neurons, CRMP5 is highly expressed in short processes
at early stages of development, resulting in inhibition at the den-
dritic but not axon level. When both CRMP5 and CRMP2 are
coexpressed, CRMP5 abrogates neurite outgrowth promotion
induced by CRMP2, thereby acting as a signal modulating
CRMP2 activity.
Materials andMethods
Recombinant protein production. The cDNA encoding full-length human
CRMP5 (residues 1-564) or truncated forms of the protein (1-520,
1-471) were amplified by PCR and inserted into the pT7-7 expression
vector, which generated a protein with six His residues at its C terminus.
The plasmid was transformed into Escherichia coli strain BL21 (DE3)
(Codon-Plus; Stratagene). The bacterial culture was grown at 37°C to an
OD600of1.8,before inductionwith75Misopropyl-D-thiogalactopyra-
noside (IPTG). After overnight incubation at 16°C, cells were harvested
by centrifugation. The pellet was suspended in buffer before disruption
by sonication and purification of the recombinant protein as described
previously (Moradi-Ame´li et al., 2002).
Crude brain extract.Postnatal day 8 (P8)mice (C57BL/6; Charles River
Laboratories) were anesthetized with pentobarbital and perfused intrac-
ardially with PBS, to clear the brain of blood. After decapitation, the
brains were removed and chilled on ice. All subsequent steps were per-
formed at 4°C. Cerebral tissue was homogenized, with aDounce homog-
enizer, in 25 mM HEPES, pH 7.2, 300 mM sucrose, 5 mM EDTA, 5 mM
DTT, 1 mM PMSF, 1 mM orthovanadate, supplemented with protease
inhibitor mixture (Complete; Roche Applied Science), and centrifuged
for 30 min at 14,000  g at 4°C. The supernatant was stored at 80°C
until used. Cortex extract was prepared as above from dissected cortex.
Antibodies used, Western blot analysis, and overlay assay. The site-
specific antibody to CRMP5 (anti-CRMP5 antibody) and CRMP2 (anti-
CRMP2 antibody) were produced in rabbits and purified as
previously described (Ricard et al., 2001). The peptide sequence used
to generate specific antisera were 505KEMGTPLADTPTRPVTRHGG524
and 454LEDGTLHVTEGS465 targeting the CRMP5 and CRMP2
C-terminal region, respectively. Other antibodies used were monoclonal
anti-MAP2 antibody (clone HM-2; Sigma-Aldrich), monoclonal anti--
tubulin (clone DM1A; Sigma-Aldrich), and anti-III-tubulin (clone
SDL.3D10; Sigma-Aldrich) antibodies. Extracts from brain, recombi-
nant protein, or immunoprecipitated proteins were resolved by SDS-
PAGE, transferred to a nitrocellulose membrane, and incubated with
different antibodies, as described previously (Rogemond et al., 2008).
Extracts from cultured hippocampal neurons, plated at a density of
1.5106 cells/well, were obtained on days 1–6 by resuspending neurons
in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1
mM sodium orthovanadate, 1% Triton X-100 supplemented with pro-
tease inhibitor mixture (Complete; Roche Applied Bioscience). After
centrifugation at 14,000 g for 30 min, the supernatant containing the
cytosolic fraction was subjected to SDS-PAGE and analyzed by Western
blot as above.
For overlay assays, purified recombinant CRMP5 was subjected to
SDS-PAGE and electrotransferred to a nitrocellulose membrane. The
membrane was incubated for 1 h in 25 mM Tris-HCl, pH 7.4, 150 mM
NaCl (TBS) containing 3% (w/v) bovine serum albumin (BSA), then
incubated overnight at 4°C with crude brain extract diluted 5 times in
TBS containing 0.1%Tween, 1mMDTT, 1mMPMSF, and 3%BSA. After
extensive washingwith TBS containing 3%BSA, the nitrocellulosemem-
brane was incubated for 1 h with anti-MAP2, anti--tubulin, or anti-
III-tubulin antibodies. After additional extensive washing, the positive
CRMP5 band was detected after an incubation for 1 h with peroxidase-
conjugated anti-mouse antibody and visualized using the ECL detection
system.
Immunoprecipitations and pull-down assays. Crude brain extract was
diluted six times in the immunoprecipitation (IP) buffer (50 mM Tris-
HCl, pH 7.4, 50 mM NaCl, 5 mM EGTA, 5 mM EDTA, 1 mM sodium
orthovanadate, 1 mM DTT, supplemented with a mixture of protease
inhibitors),mixedwith themonoclonal anti-MAP2, anti-- or anti-III-
tubulin antibodies, and incubated overnight on a rocking platform at
4°C. Then, 150 l of protein A-Sepharose 6MB (Sigma-Aldrich) was
added to 1 ml of mixture and immunoprecipitation allowed to proceed
for 1 h at 4°C. After a short spin at 14,000 g at 4°C, the supernatant was
removed, and the beads were washed six times with 1ml of IP buffer. The
beads were then suspended in sample buffer, boiled for 5 min, and sub-
jected to SDS-PAGE and Western blotting.
For pull-down assays, cDNA fragments encoding the full-length (res-
idues 1-564), N-terminal part C472 (residues 1-471), C-terminal half
N244 (residues 245-564), and C-terminal part N474 (residues 475-
564) of human CRMP5 or full-length human CRMP2 were inserted
downstream of the GST gene in the pGEX-6P-1 vector (GE Healthcare).
All fragments were confirmed by DNA sequencing. E. coli BL21 (DE3)
cells transformed with each plasmid were cultured to reach an OD600 of
0.6, before induction with 0.4 mM IPTG. After 4 h of incubation at 37°C,
cells were harvested by centrifugation and suspended in lysis buffer be-
fore disruption by sonication. GST-fused CRMP2 or CRMP5 derivatives
were purified from the cell lysate, by adsorption onto glutathione Sepha-
rose 4B beads (GE Healthcare). To demonstrate direct interaction be-
tween CRMP5 and tubulin, GST-CRMP5 derivatives (25 g/ml)
conjugated to glutathione Sepharose 4B (50% slurry, diluted 20 times)
were incubated with purified tubulin (100 g/ml; Cytoskeleton) in PBS,
1 mM dithiothreitol, 1 mM PMSF, 20% glycerol, and 0.1% Triton X-100
for 1 h at 4°C. The beads were pulled down by centrifugation and washed
thoroughly with buffer, and then subjected to SDS-PAGE and Western
blotting. For the assay using mouse brain extract, the GST-CRMP5 de-
rivatives were incubated overnight at 4°C with P8 mouse brain extract
(diluted five times), instead of purified tubulin. To study the effect of
CRMP5 on tubulin–CRMP2 interactions, GST-CRMP2, conjugated to
glutathione Sepharose 4B, was incubated with purified tubulin for 10
min at 4°C, followed by additional incubation with increasing amounts
of purified recombinant His-CRMP5 for 1 h at 4°C and treated as above.
Tubulin polymerization assay. Purified bovine brain tubulin (6 mg/ml;
Cytoskeleton) was reconstituted in tubulin buffer (TB) containing 80
mM PIPES, pH 6.9, 2 mMMgCl2, 0.5 mM EGTA, and 5% glycerol. Tubu-
lin, diluted twofold with purified recombinant CRMP5 equilibrated in
TB, was incubated for 20 min at 4°C before starting the polymerization
reaction by adding GTP (1 mM) at 37°C. Control incubations contained
the TB buffer instead of CRMP5 protein. The ability of tubulin to poly-
merize intomicrotubules wasmonitored by the increase in absorbance at
340 nm versus time, with a Cary 100 Scan spectrophotometer (Variant)
thermostated at 37°C.
Expression constructs, cell culture, and transfection. Full-length CRMP2
or CRMP5 were amplified by PCR and inserted directionally into the
pCMV2-FLAG vector (Sigma-Aldrich), which generated a protein
with a FLAG tag at its N terminus, essentially as described previously
(Rogemond et al., 2008). Full-length EGFP-CRMP5 or different deletion
mutants were amplified by PCR introducing EcoRI and NotI restriction
sites. cDNA fragments encoding full-length human CRMP5, N244
CRMP5, C472 CRMP5, and C518 CRMP5 were digested by EcoRI
and NotI and sequentially ligated into pCEFL-tagged EGFP vectors,
which generated a protein with enhanced green fluorescent protein
(EGFP) at itsN terminus. The sequences of all constructs were confirmed
by automated DNA sequencing. PC12 cells were transfected with puri-
fied plasmids containing FLAG-tagged CRMP5, EGFP, or EGFP-tagged
CRMP5 derivatives as described previously (Rogemond et al., 2008). At
8 h after transfection, PC12 cells were stimulated by 100 ng/ml NGF (7S;
Sigma-Aldrich), for up to 36 h. N1E-115 cells were transfected with the
above plasmid constructs, or FLAG-tagged CRMP2 using Lipofectamine
LTX (Invitrogen) as described previously (Rogemond et al., 2008), and
fixed at 48 h after transfection.
Primary culture of hippocampal neurons. Hippocampal neurons from
embryonic day 18 (E18) mouse embryos were prepared and plated at a
density of 3  105 cells/well as previously described (Yoshimura et al.,
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2005). In one set of experiments, neurons were transfected 24 h after
platingwith EGFP, EGFP-taggedCRMP5, or FLAG-taggedCRMP2plas-
mid constructs using the Nanojuice kit (Novagen; Merck) and fixed 48 h
later at 3 d of in vitro culture (DIV 3), before staining. In another set of
experiments, neurons were cultured for 4 d before single transfection
with the above plasmid constructs or double transfection with both
EGFP-tagged CRMP5 derivatives and FLAG-tagged CRMP2 constructs
using Lipofectamine LTX. Hippocampal neurons were fixed 48 h after
transfection at DIV 6 before immunolabeling.
Immunocytochemistry and morphology assay. Cells were fixed in 4%
paraformaldehyde (PFA) for 20 min at 4°C and blocked with PBS con-
taining 2% BSA and 0.1% Triton X-100 before staining. PC12 cells were
double-stained with polyclonal anti-FLAG (Sigma-Aldrich) and anti-
rabbit Alexa Fluor 488 (Invitrogen) andwithmonoclonal anti--tubulin
and anti-mouse Alexa Fluor 555 antibodies, respectively. In some stud-
ies, anti-CRMP5 antibody was used to label endogenous CRMP5. PC12
cells were observed using a laser-scanning confocal system (Leica TCF
SP2 imaging platform). For morphometric analysis, PC12 cells were
transfected with EGFP-CRMP5 constructs (full-length or different mu-
tants of CRMP5 N244, C472, and C518) and observed by green
fluorescence emission without additional staining, using an Axioplan II
fluorescence microscope (Carl Zeiss). The percentage of transfected
PC12 cells exhibiting rounded shapes or bearing neurite-like extensions
less than and greater than 10 m was measured.
N1E-115 cells transfected with FLAG-tagged constructs, were stained
using monoclonal anti-FLAG (Sigma-Aldrich), followed by anti-mouse
Alexa Fluor 488 (Invitrogen) antibodies. In double-transfection experi-
ments, FLAG-tagged CRMP2 was stained using anti-mouse Alexa Fluor
555 antibody, whereas EGFP-tagged CRMP5-transfected cells were ob-
served by green fluorescence emission. The percentage of CRMP5-
expressing cells bearing neurite length 25 m from the cell body was
measured in each transfection and compared with EGFP-expressing
and/or CRMP2-expressing cells. N1E-115 cells were observed with the
fluorescence microscope.
Hippocampal neurons, at either DIV 3 orDIV 6, were fixed in 4%PFA
for 20min at room temperature, and stained after single or double trans-
fection as described above. To identify dendrites and axons in each set of
experiments, labelingwas performed using anti-MAP2, followed by anti-
mouse Alexa Fluor 555 and anti-tau (clone H-150; Santa Cruz Biotech-
nology), followed by anti-rabbit Alexa Fluor 350 antibodies, respectively.
The length of longest neurite was measured as that of axon. The percent-
age of neurons for which the second longest neurite was more than
one-half the length of the longest neurite, was counted as that ofmultiple
long neurites. The length of all remaining shorter neurites of an individ-
ual neuron, beginning from the cell body, was measured as that of den-
drite. For morphometric analysis, the images of labeled neurons were
captured with the fluorescence microscope, and the axons and their
branching, as well as dendrites, were traced on a video screen and ana-
lyzed using analysis Image Processing 3.2 software.
Evaluation of CRMP5, and CRMP2 spatiotemporal distribution in cul-
tured hippocampal neurons.Hippocampal neurons from E18 mouse em-
bryos were plated at a density of 5 104 cells/well as above and fixed on
days 1–6 of in vitro culture (DIV 1–6). To follow CRMP5, CRMP2, and
MAP2 expression at different time intervals, hippocampal neurons were
double stained with anti-CRMP5 and anti-CRMP2 or anti-MAP2 fol-
lowed by anti-rabbit Alexa Fluor 488 and anti-mouse Alexa Fluor 555
antibodies, respectively. Images of fluorescent neurons were captured
with an Axioplan II fluorescence microscope. To determine the fluores-
cence intensity, all fluorescent images were digitally converted into a
grayscale image before the analysis. Quantitative measurements of fluo-
rescence intensities were obtained by averaging the intensity of different
40  40 square areas of pixel intensities obtained from defined area
across axon and dendrites, but no cell bodies, using image processing,
ImageJ 1.42q software. The grayscale intensity was corrected against the
intensity point of the background. Numerical fluorescence values were
graphed as fluorescence intensity for CRMP5, CRMP2, or MAP2 at DIV
1–6. For three-dimensional intensity projection, individual neurons
were manually selected and the optical center of mass was used to center
themeasurement box (1376 1032 pixels). Areas for imaging contained
cell bodies and networks of dendrites and axon. The luminance of an
image was interpreted as the height for the plot.
Knockdown of gene expression by small interfering RNA.Validated small
interfering RNA (siRNA) against rat CRMP5 (5-GTTTCAGCCTCT-
CTGGTTC-3) sequence (Hotta et al., 2005) and control (scrambled
sequence with the same percentage of CG but no sequence homology)
were purchased from Invitrogen. N1E-115 cells or hippocampal neurons
were transfected 24 h after plating with 100 nM vector-siRNA or scram-
bled siRNA (SC) using the Ribojuice kit (Novagen). N1E-115 cells were
fixed 36 h after transfection and stained with phalloidin and 4,6-
diamidino-2-phenylindole (DAPI) to label the F-actin and nuclei, re-
spectively. Hippocampal neurons were transfected either with siRNA
and EGFP and observed by green fluorescence emission or with siRNA
and FLAG-CRMP2 plasmid construct and stained with anti-FLAG and
anti-mouse Alexa Fluor 555 antibodies. In neurons, the transfection was
performed with the simultaneous use of Ribojuice and Nanojuice kits
(Novagen).
Statistical analyses.Differences between means were compared by un-
paired two-tailed Student’s t test. Data are expressed as mean SE, with
p 0.05 considered as the level of significance. Data are the mean values
of at least three individual experiments.
Results
CRMP5 binding toMAP2 and tubulin
To identify CRMP5-interacting proteins in the developing ner-
vous system, we searched for high-molecular-weight proteins,
from P8 mouse brain extract, which copurified with CRMP5 on
an affinity column (Cibacron Blue agarose). Among different
proteins eluted from this column and subjected to SDS-PAGE, a
band migrating with an apparent molecular mass of 270 kDa
was excised, subjected to mass spectrometry, and identified as
MAP2 (data not shown). The CRMP5–MAP2 interaction was
confirmed by the coimmunoprecipitation of CRMP5 by anti-
MAP2 antibody in a lysate from the brain cortex of P8 mouse.
Western blotting of the immunoprecipitate showed that the band
migrating with an apparent mass of 66 kDa was recognized by
anti-CRMP5 site-specific antibody (Fig. 1A). The use of two
other monoclonal antibodies against the N-terminal and
C-terminal parts of CRMP5 further confirmed the 66 kDa band
as CRMP5 (data not shown). Two forms of MAP2 can be distin-
guished in the neonatal stage: high-molecular-weight MAP2b
and low-molecular-weight MAP2c. As a control, both forms of
MAP2 were also precipitated by the anti-MAP2 antibody (Fig.
1A). This is consistent with the colocalization of MAP2 with
CRMP5 previously reported in the dendrites of embryonic corti-
cal neurons in culture, as well as in the brain cortex of adults
(Bretin et al., 2005).
As MAP2 was the major microtubule-associated protein of
brain tissue, we assessed whether tubulin was present in the im-
munoprecipitate formed by MAP2 and CRMP5. A band corre-
sponding to tubulin was detected using -tubulin antibody,
thereby indicating the presence of tubulin as well as MAP2 and
CRMP5 in the immunoprecipitate (Fig. 1A). Next, we examined
the expression patterns of CRMP5 and tubulin on NGF-induced
differentiated PC12 cells transfected with the FLAG-CRMP5 ex-
pression vector. As the distribution of MAP2 in PC12 cells was
well known (Brugg and Matus, 1988), we did not investigate its
expression pattern in this study. Immunofluorescence labeling
using anti-FLAG and anti--tubulin antibodies showed that
CRMP5 was clearly colocalized with -tubulin (Fig. 1B, left and
middle panels). However, after close examination, it seemed that
this colocalization did not extend to theminormembrane exten-
sions, since clear green staining, corresponding to CRMP5 ex-
pression, could be observed in the merge images of the
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transfected cells (Fig. 1B, high magnifica-
tion in left panels). Endogenous CRMP5
labeled with anti-CRMP5 antibody also
showed a clear overlapping expression
with tubulin (Fig. 1B, right panels).
We then performed coimmunopre-
cipitation assays using -tubulin and
III-tubulin antibodies. CRMP5 was un-
ambiguously coimmunoprecipitated from
brain lysate by both antibodies (Fig. 1C).
To further confirm these interactions,
we performed an overlay experiment in
which recombinant CRMP5 protein was
transferred to a nitrocellulose membrane,
and then subsequently incubated in the
presence or absence of brain lysate, before
the detection of CRMP5-bound proteins
with different antibodies. In the presence
of brain lysate, CRMP5 bound strongly to
MAP2 and-tubulin (Fig. 1D). However,
anti-III-tubulin detected the CRMP5
protein as a faint band, indicative of a
weak interaction. Reciprocally, -tubulin
andMAP2 were pulled down from lysates
of brain cortex usingGST-CRMP5 immo-
bilized on glutatione-Sepharose beads,
suggesting their coassembly in vivo. Fig-
ure 1E shows that GST-CRMP5, but not
GST, precipitates -tubulin, which is present
in the supernatant fractions of both GST
and GST-CRMP5. Similarly, incubation
of GST-CRMP5 with brain lysate led to
the coprecipitation of two forms of MAP2,
MAP2b and MAP2c (Fig. 1E), albeit at
lower levels than that of tubulin. Together,
the above data suggest the formation of a
ternary complex between CRMP5, tubulin,
and MAP2. However, within this complex,
the CRMP5-interacting molecule is not
distinguished.
Identification of a direct interaction
between the C-terminal domain of
CRMP5 and tubulin
We examined whether the CRMP5-MAP2
coassembly was mediated by tubulin sub-
units, this hypothesis being reinforced by
the fact that tubulin binding to CRMP1-4
had previously been reported (Fukata et
al., 2002). An in vitro binding assay was
performed using recombinant GST-CRMP5
and purified tubulin, containing both
- and -tubulin. Both -tubulin and -
tubulin were pulled down by GST-
CRMP5 (Fig. 2A), demonstrating a direct
interaction between CRMP5 and - and
-tubulin. However, -tubulin showed
greater binding to CRMP5 than -tubu-
lin. To identify the CRMP5 domain responsible for mediating
interactions with tubulin, deletion constructs of CRMP5 were
designed (Fig. 2B), and purified proteins generated as GST-
CRMP5 (Fig. 2C) were used in an in vitro binding assay. After
incubation of the purified tubulin with these mutated CRMP5-
GST constructs (Fig. 2D, top panel), tubulin was found to bind
strongly to the full-lengthCRMP5(aminoacids1-564),N-terminal-
deleted mutants N244 (245-564) and N474 (475-564), but not
to the C-terminal-deleted mutant C472 (1-471). The most
C-terminal 90 aa fragments of CRMP5 (475-564) coprecipitated
Figure 1. CRMP5 interacts with MAP2 and tubulin. A, Brain extract from P8 mice was immunoprecipitated by anti-MAP2
antibody, and Western blots were probed for CRMP5 and-tubulin immunoreactivity. CRMP5 and tubulin were coimmunopre-
cipitated in a complex with MAP2 protein. Immunoprecipitation of MAP2 is shown as positive control. Note the absence of
reactivity in the control IgG.B, Endogenous andoverexpressed CRMP5 colocalizedwith tubulin inNGF-induceddifferentiatedPC12
cells. Left panel, Cells transfected with FLAG-CRMP5 and immunostained with anti--tubulin and anti-FLAG antibodies show
colocalization of CRMP5 and tubulin in the cytosol and in thin extensions. The inset is a magnification of this area. Middle panel,
High magnification of one PC12 cell clearly shows colocalization of CRMP5 and tubulin. Right panel, Endogenous CRMP5 colocal-
ized with tubulin at the cytosolic level and in thin extensions. The inset is a magnification of one PC12 cell. Scale bars, 20m. C,
Immunoprecipitation of brain extract from P8 mice with anti-- or anti--tubulin antibodies. Western blots were probed for
CRMP5 immunoreactivity. CRMP5 was immunoprecipitated in a complex with- and-tubulin. As expected,- and-tubulin
were also coimmunoprecipitated with anti-- and anti--tubulin antibodies, respectively. Control IgG failed to precipitate any
protein. D, Overlay assay using purified recombinant CRMP5 (15 g) subjected to SDS-PAGE and transferred to nitrocellulose
membrane. After an overnight incubation with brain extract from P8 mouse (	) or buffer (), the membrane was probed for
MAP2,-tubulin, orIII-tubulin immunoreactivity. CRMP5 interacts with MAP2,-tubulin, orIII-tubulin present in the brain
extract. The intensity of interaction is higher for MAP2 and-tubulin than forIII-tubulin. E, Pull down of tubulin from mouse
brain extract with GST or GST-CRMP5 (10g) conjugated to glutathione Sepharose 4B beads. Western blots of the pellet were
probed for tubulin andMAP2 immunoreactivity. GST-CRMP5, but not GST, precipitated MAP2 and-tubulin. Each result is repre-
sentative of three to five separate experiments with similar results.
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with tubulin more strongly than the full-length form and any of
the other mutants (Fig. 2D). The same binding pattern could be
observed when the above pull-down assays with GST-CRMP5
were performed using a lysate from brain cortex instead of puri-
fied tubulin (Fig. 2D, bottom panel), thus ensuring that the iden-
tified tubulin-binding site was also valid in vivo. To determine the
shortest effective fragment for tubulin binding, we generated two
GST-CRMP5 additional fragments, 475–522 and 523–564, which
were immobilized on beads and incubated with purified tubulin.
Fragment 523-564 failed to pull down the tubulin, whereas frag-
ment 475–522 did (Fig. 2E). These data demonstrate that the
tubulin-binding site on CRMP5 was located in a 48 aa fragment
in the C-terminal region within residues 475-522. A recent study
identified a tubulin-binding site within residues 480-509 of the
CRMP2 sequence (Chae et al., 2009). Comparison between the
CRMP5 and CRMP2 sequences within the region encompassing
tubulin binding indicated that, despite a strong sequence identity
between CRMP5 and CRMP2 on both sides of the identified site,
only a weak sequence homology within the identified site could
be observed (supplemental Fig. S1, avail-
able at www.jneurosci.org as supplemen-
tal material).
To gain insight into the spatial orga-
nization of this site, the structure of
CRMP5(residues8-483)wasmodeled using
DHPase as a template and the structure of
the C-terminal part (residues 484-552)
was predicted as an “intrinsically unstruc-
tured protein” using the NORS predic-
tion program. Within the tubulin-binding
site, residues 475-478 formed the most
C-terminal part of the last helix, whereas
the following residues (484-522) seemed
to be unstructured (supplemental Fig. S2,
available at www.jneurosci.org as supple-
mental material) giving the molecule a
malleable and flexible structural state, and
importantly facilitating its interaction
with other proteins. This region seems to
be surface exposed.
CRMP5 acts as an inhibitor of neurite
outgrowth and formationmediated by
tubulin binding
Since one of the functions reported for
some CRMPs is the promotion of neurite
outgrowth mediated by tubulin binding
(Fukata et al., 2002), we examined the ef-
fect of CRMP5 on neurite outgrowth ac-
tivity by transfecting neuroblastoma cells
(N1E-115) with the FLAG-CRMP5 ex-
pression vector. In parallel, we performed
transfectionwith CRMP2, which has been
reported to promote neurite outgrowth
(Suzuki et al., 2003; Rogemond et al.,
2008). After immunostaining with the
anti-FLAG antibody, the lengths and
numbers of neurite-like extensions were
compared with the control EGFP-trans-
fected cells. CRMP2-transfected cells
showed, as expected, polygonal shapes
presenting longer neurites 25 m (Fig.
3A). The CRMP5-expressing cells (n 

206) showed mostly an overall round shape. They clearly dis-
played less neurite elongation (3.5-fold) and also reduced the
number of neurites per cell (2-fold) compared with the control
EGFP-expressing cells (**p 0.01), as shown in Figure 3, D and
E. For additional examination of CRMP5 function, we depleted
the CRMP5 protein in N1E-115 cells, by siRNA interference. The
effect of siRNA against CRMP5 (siCRMP5) was first confirmed
by immunoblot analysis (Fig. 3B). The immunostaining of en-
dogenous CRMP5 in cells treated with the scrambled siRNA (SC,
n
 150 cells) showed a clear green staining indicative of CRMP5
expression, whereas the absence of green staining in siCRMP5-
treated cells (n
 100 cells) revealed that CRMP5 expression was
totally impaired (Fig. 3C, top panels). To evaluate neurite length,
the cells were also stained by phalloidin (red). Knockdown of
CRMP5 (Fig. 3C, bottom panels; D,E) drastically increased not
only the neurite elongation (3.5-fold) but also the number of
neurites per cell (3-fold) compared with SC (***p  0.005). To
confirm that these effects were attributable to CRMP5 depletion,
we performed rescue experiments by overexpressing EGFP-
Figure 2. CRMP5 interacts directly with tubulin within C-terminal residues 475-522. A, Pull down of purified tubulin
protein (40g) with GST or GST-CRMP5 (10g) conjugated with Sepharose beads. Western blots were probed by anti--
or anti--tubulin antibodies. Tubulin subunits were precipitated by GST-CRMP5, but not GST, indicating a direct interac-
tion between CRMP5 and tubulin. B, Diagram depicting CRMP5 truncationmutants. C, SDS-PAGE showing each GST-CRMP5
truncated protein confirms the correct mass for recombinant proteins. The bars on the left indicate the positions of
molecular markers. The arrows on the right indicate the apparent molecular mass of each GST-taggedmutant. D, Pull down
of purified tubulin (top panel) or tubulin from mouse brain extract (bottom panel) incubated with different truncated
GST-CRMP5 recombinant proteins, shown in C. Western blots of the pellets, probed with an anti--subunit antibody, show
that tubulin, purified or present in the brain extract, interacts with all truncated forms of CRMP5 except CRMP5C472. The
presence of the C-terminal residues 475-564 is sufficient to ensure tubulin pull down. Tubulin is present in the supernatant
fraction of all assays. E, Pull down of tubulin with the shorter fragments of recombinant GST-CRMP5. The shortest frag-
ment, which precipitates tubulin, is encompassed by residues 475-522 of CRMP5.
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CRMP5 in siCRMP5-transfected cells
showing strong level of CRMP5 expres-
sion (supplemental Fig. S3, available at
www.jneurosci.org as supplemental ma-
terial). In this case, the negative effect of
CRMP5 on the elongation and number of
neurites was rescued by restoring the ex-
pression level of CRMP5, since the N1E-
115 cells again presented an overall round
shape (Fig. 3C, right panel; D,E). To-
gether, these data suggested that CRMP5
is involved in neurite retraction as well as
neurite formation in N1E-115 cells.
To determine the impact of the
tubulin-binding region of CRMP5 on its
inhibitory function, we examined the
neurite-like extensions, in NGF-stimu-
lated PC12 cells expressing different EGFP-
deleted constructs of CRMP5. Since the
average length of neurite extension after
48 h of NGF induction was 10 m in
PC12 cells (Fontaine-Lenoir et al., 2006),
this limit was chosen for the evaluation of
neurite length. Confocal analysis showed
that, comparedwithGFP-expressing cells,
the cells expressing full-length CRMP5
(n
 157 cells) exhibited a lower percent-
age (9% instead of 30%) of neurite lengths
exceeding 10 m (**p 0.01) but a higher
percentage (36% over 27%) of extensions
10m(Fig. 4A,B). Similarly, only a small
percentage of the cells bearing neurites10
min length couldbeobserved among cells
expressing N-terminally truncated CRMP5
(N244), bearing the tubulin-binding do-
main (n
 95 cells), and the CRMP5 con-
structC518 (n
 136 cells), bearing only
a few additional residues responsible for
tubulin binding (Fig. 4A,B). These cells
also display an overall round morphology
(73–75%). In contrast, cells expressing the
CRMP5 construct C472, lacking the
tubulin-binding domain (n 
 93 cells),
exhibited polygonal shape and induced
neurite extensions whose lengths were
comparable with EGFP-expressing cells
(Fig. 4A, bottom panels). Moreover, the
number of neurite-like extensions per cell
also decreased when cells expressed con-
structs bearing the tubulin-binding site,
and increased to control levels when cells
expressed the C472 construct lacking
this site (Fig. 4C). It should be noted that
the latter form was present in the nucleus
as well as in the cytosol. These data
strengthen the hypothesis that the tubulin-
binding region of CRMP5 is responsible for
its inhibitory function in neurite outgrowth
and formation.
Wenext examined the effectofCRMP5 in
hippocampal neurons from E18 mouse
embryos transfected with EGFP-CRMP5
on day 4 after plating, and immuno-
Figure 3. CRMP5 induces inhibition of neurite outgrowth and formation in N1E-115 cells. A, Cells were transfected with EGFP
alone (top panel) or with FLAG-CRMP5 (middle panel) and FLAG-CRMP2 (bottom panel), and then labeled by anti-FLAG antibody
and observed by fluorescent microscopy. The nucleus is stained blue with DAPI. Although N1E-115 cells transfected with EGFP
present a polygonal shape and exhibit some neurite extensions, cells expressing CRMP5 present round cell morphologies. As
reported, cells expressing CRMP2 clearly exhibit longer neurite extensions. The typical pattern of immunostaining is shown in
high-magnification images in three right panels. Scale bar, 50m.B, Knockdownof CRMP5 expression by siCRMP5. N1E-115 cells
were transfected or not with scrambled siRNA (SC) or siCRMP5, and CRMP5 expression was probed by anti-CRMP5 antibody. The
GAPDH antibody is used as loading control. Note the complete depletion of CRMP5 expression after siCRMP5 treatment. C, CRMP5
depletion induces long neurite. Endogenous CRMP5 was detected by immunostaining with anti-CRMP5 antibody in SC-treated
cells, whereas CRMP5 labeling was absent from siCRMP5-treated cells (top panels), detected by DAPI staining. A double staining
with phalloidin, shows unambiguously the presence of longer neurite in siCRMP5-treated cells compared with SC cells (bottom
panel). The CRMP5 inhibition of the neurite outgrowth is rescued by overexpression of CRMP5 in siCRMP5-treated cells (right
panel). Scale bar, 50 m. D, E, Quantification of neurite length and number after overexpression or knockdown of CRMP5. D,
Comparison of neurite outgrowth between N1E-115 cells expressing EGFP (n
 77), overexpressing CRMP2 (n
 248) or CRMP5
(n
 206), or transfected with siCRMP5 (n
 100) or SC (n
 157). Overexpression of CRMP5 leads to a significant decrease in
neurite outgrowth initiationwhen comparedwith controls, whereas CRMP2 promotes neurite extension; however, knockdown of
CRMP5 induces an increase in neurite length when compared with cells treated with the control SC. E, Comparison of neurite
numbers per cell after overexpression or knockdown of CRMP5 as for D. Overexpression or knockdown of CRMP5 generates a
decrease or increase in the neurite number per cell, respectively. Data show the mean values of four individual experiments,
expressed as cells bearing neurite lengths25m (**p 0.001; ***p 0.005). Error bars indicate SEM.
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stained 2 d later at DIV 6, which corresponded to stage 4 of
hippocampal neuron development in culture. This stage corre-
sponded generally to the establishment of distinct dendritic do-
main in cultured neurons (Dotti et al., 1988). Control EGFP
neurons showed one fast-growing axon
and shorter neurites considered as den-
drites, although immature, at this stage
(see Fig. 6A). Double staining of the cells
using antibodies to the axonal marker
anti-tau1 and the somato-dendritic
marker anti-MAP2 confirmed that the
long neurite was the axon and the other
neurites were dendrites (see Fig. 6B).
CRMP5 transfection did not significantly
change axon length and branching but re-
duced by 20% the length of dendritic pro-
cesses (n 
 42 neurons). Consistent with
the above data, transfection with CRMP5
C518, bearing the tubulin-binding do-
main, reduced dendrite length by 40%
(*p  0.05), whereas the C472 mutant,
devoid of this domain, had no effect on
dendrite length (see Fig. 6A,C). These
data suggest that the tubulin-binding re-
gion of CRMP5 is necessary for the in-
hibition of dendrite growth. Although
CRMP2 enhanced the number of den-
drites, CRMP5 showed no effect on den-
drite formation at stage 4 since the
number of dendrites per neuron is com-
parable with the control (see Fig. 6D).
The absence of effect on dendrite for-
mationmay be explained by the fact that
at stage 4 the dendritic domains were
established.
To determine whether the tubulin–
CRMP5 interaction exerted an influence
on tubulin polymerization, we performed
an in vitro assay to evaluate the capacity of
purified tubulin to polymerize into mi-
crotubules, in the presence or absence of
recombinant CRMP5 protein. A trun-
cated form of CRMP5 (C521) was over-
expressed since, as indicated above, this is
themost active form in neurite retraction.
Purified control tubulin started to poly-
merize in the presence of GTP after a time
lag of60 s, with a steep initial slope dur-
ing the first 7min, followed by an increase
up to a variation of optical density (OD)
of 0.47 after 15 min (Fig. 4D). The addi-
tion of truncated recombinant CRMP5
before the polymerization step delayed
tubulin polymerization, since the initial
rate of microtubule formation was slower
and the OD was 34% lower than the
control level. Moreover, even after pro-
longed incubation, theODdid not reach a
plateau level (Fig. 4D). To ascertain the
specific effect of the CRMP5 tubulin-
binding site, a polymerization assay was
performed in the presence of CRMP5
C472, which showed very similar tubu-
lin polymerization to control tubulin. A similar pattern ofmicro-
tubule formation was observed in the presence of bovine serum
albumin, as a control, with a plateau reached at a OD of 0.45
(Fig. 4D).
Figure 4. Tubulin binding is required for the inhibition of neurite outgrowth by CRMP5. A, PC12 cells transfected by the
CRMP5 EGFP-tagged constructs were stimulated 8 h later with NGF for 36 h, and then fixed and observed by confocal
microscopy. Cells transfected with full-length CRMP5, or truncated mutant N244 and C518 constructs, bearing the
tubulin-binding site, show rather round shapes and retracted extensions. However, when the tubulin-binding site is
deleted (CRMP5C472), the cells fail to retract and remain spread. Scale bars, 20m. B, Quantification of neurite length
in PC12 cells from A. The percentage of round-shaped cells or cells bearing neurite lengths greater than or less than 10m
is shown for each construct. Below the graph is a diagram of truncated CRMP5 forms with the tubulin-binding site shown
by a red box. The presence of a tubulin-binding site is necessary for neurite retraction activity. Cells expressing full-length
CRMP5,N244, orC518 (n
 157, 95, and 136 cells, respectively) show a high percentage of round shapes (54 –75%)
and a low percentage exhibiting neurite extensions10 m (6 –9%). In contrast, in CRMP5 C472-expressing cells
(n
 93), the percentage of round shape is lower (36%) and cells with neurite extension10 m are more abundant
(25%). Between 19 and 36% of all cells have neurites 10m. Data are the mean values of three individual experiments.
**p 0.001 versus control EGFP value. C, Quantification of neurite number per cell. Overexpression of different forms of
EGFP-CRMP5 bearing the tubulin-binding site lead to a decrease in the number of neurites per cell (20 –70%), whereas
overexpression of CRMP5C472 has no effect (*p 0.05; **p 0.001). Error bars indicate SEM. D, The inhibitory effect
of truncated recombinants CRMP5C521 on tubulin polymerization in vitro. Microtubule assembly was monitored at 340
nm at 37°C and recorded every 30 s. The quantity of microtubules formed is proportional to the increase in absorbance.
Polymerization of purified tubulin protein (3 mg/ml) was recorded either without (a) or with 4.3 M CRMP5 C521 (b),
CRMP5 C472 (c), or 4 M BSA (d) for 20 min. Data represent means for four independent observations. CRMP5 C521
inhibits microtubule assembly, whereas CRMP5C472 and BSA have no effect.
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CRMP5 inhibition of neurite outgrowth is not counteracted
by CRMP2 expression
To evaluate the effect of CRMP5 when CRMP2 was present, we
cotransfected N1E-115 cells with both GFP-CRMP5 and FLAG-
CRMP2 expression vectors, cells coexpressing both proteins be-
ing identified by their yellow color (Fig. 5A). A small percentage
of CRMP5-expressing cells (4%) showed neurite lengths 25
m(**p 0.01), whereas this percentage was higher (20.4%) for
CRMP2-expressing cells (Fig. 5B). Remarkably, cells coexpress-
ing both CRMP2 and CRMP5 (n
 79) presented short neurite-
like extensions, since only 5.3% displayed neurite lengths
25 m (Fig. 5A, top panels; B). Strikingly, 70% of double-
transfected cells exhibited rather round shapes. These data sug-
gest that CRMP5 acts as a dominant signal to counteract the
neurite outgrowth promotion activity of CRMP2. The double
transfection of cells with CRMP2 and truncated forms of CRMP5
harboring the tubulin-binding site resulted in a low percentage of
cells exhibiting long neurites, whereas double transfection with
CRMP2 plus CRMP5 C472, devoid of the tubulin-binding site,
resulted in a high percentage of cells (24%) displaying extensions
longer than 25 m (***p  0.005) (Fig. 5A, bottom panels; B).
These results suggest that the abrogation of neurite outgrowth
function of CRMP2 by CRMP5 is also dependent on the tubulin-
binding capacity of CRMP5.
We next examined the effect of CRMP5 relative to CRMP2 in
hippocampal neurons transfected with EGFP-CRMP5 and/or
FLAG-CRMP2, and immunostained at DIV 6, as mentioned
above. In accordance with previous reports (Fukata et al., 2002),
hippocampal neurons expressing CRMP2 showed a significant
increase in both axon length and the frequency of axonal branch-
ing with the cells sometimes displaying secondary axons (Fig.
6A,C,E). Detailed dendrite length measurements showed that
CRMP2 increased the length of dendrites 1.4-fold comparedwith
control (Fig. 6C). Strikingly, when CRMP2 and full-length
CRMP5 were coexpressed (n 
 46 neurons), axon elongation
and dendrite length decreased to the level of CRMP5 expression
alone (***p 0.001), strengthening the hypothesis that CRMP5
abrogates CRMP2 promotion of neurite outgrowth in a domi-
nant manner (Fig. 6C,F). However, after close examination, the
dominant effects of CRMP5 were more pronounced in dendrites
than in axons. In fact, although therewas less axon branching and
fewer secondary axons in double-transfected compared with
CRMP2-expressing neurons, they reached a level situated some-
where between CRMP2 and CRMP5 expression alone (Fig. 6E).
To elucidatewhether the tubulin-binding domain of CRMP5was
involved in the inhibition of CRMP2 function, hippocampal
neurons were cotransfected with CRMP2 and different truncated
forms of CRMP5 (Fig. 6F). Importantly, neurons cotransfected
with CRMP2 and C518 CRMP5, containing the tubulin-
binding domain, reduced dendrite and axon length to the level of
CRMP5 expression alone, indicating that this form abrogated the
CRMP2 promotional outgrowth of axon and dendrites. On the
contrary, neurons cotransfected with CRMP2 and CRMP5
C472, lacking the tubulin-binding domain (n 
 60 neurons),
showed significant increases in axon length and dendrite out-
growth (***p  0.0005) approximately equal to the level of
CRMP2 expression alone (Fig. 6A,C,F), indicating that when the
tubulin-binding domain was missing, CRMP5 was unable to
counteract CRMP2 function. These data suggest that CRMP5
abrogates the neurite outgrowth promotional activity of CRMP2
at both the dendrite and axon levels, and this effect seems to be
mediated by the tubulin-binding capacity of CRMP5 in hip-
pocampal neurons.
The role of microtubule in the extension of neuronal process
has been previously well established (Yamada et al., 1970). More
recently, the interaction of tubulin with CRMP2 was reported to
promote the axon growth (Fukata et al., 2002). Therefore, to
examine the molecular mechanisms that generate the antagonis-
tic effect of CRMP5 on CRMP2, in vitro binding assays were
Figure 5. CRMP5 neurite outgrowth inhibition abrogates the CRMP2 promotion function in
N1E-115 cells. A, Cells were cotransfected with GFP-CRMP5 and FLAG-CRMP2 constructs, la-
beled with anti-FLAG antibody (red), and observed with fluorescent microscopy. Only the cells
transfected with both vectors are yellow in the merge image. Note that the cells transfected
with CRMP2 alone, which remained red, exhibited some neurite-like extensions. Cells cotrans-
fected with full-length CRMP5,N244, orC518 and CRMP2 clearly show a round morphol-
ogy. Cells double transfected with CRMP5C472 and CRMP2 show a polygonal shape. Scale
bars, 50 m. B, Quantification of cells from A exhibiting neurite lengths25 m. CRMP5
decreases, but CRMP2 increases the percentage of cells bearing longer neurite lengths. In the
presence of both CRMPs, the cells (n
 79) show rather a low percentage of longer neurites,
indicating the dominant effect of CRMP5 when bearing the tubulin-binding site. However,
when CRMP5C472 and CRMP2 are overexpressed, the percentage of cells with longer neurite
lengths reaches the value of CRMPP2 expression alone, suggesting that the antagonizing effect
of CRMP5 is exerted through a tubulin-basedmechanism (**p 0.001; ***p 0.0005). Error
bars indicate SEM.
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performed to elucidate whether CRMP5
had an effect on the tubulin–CRMP2 in-
teraction. This interaction was assessed
using recombinant GST-CRMP2 and pu-
rified tubulin in the presence of increasing
concentrations of purified full-length or
truncated forms of CRMP5, eitherC472
or a newly designed oneC521, generated
asHis-CRMP5 (Fig. 7A). As expected, pu-
rified tubulin was pulled down by GST-
CRMP2 (Fig. 7B). When GST-CRMP2
and purified tubulin were subsequently
incubatedwith either full-length orCRMP5
C521, the binding of tubulin to CRMP2
decreased with increasing amounts of
CRMP5 (Fig. 7B), indicating that CRMP5
impaired the tubulin–CRMP2 interaction.
The antagonizing effect of C521 was
more pronounced than the full-length
CRMP5 (Fig. 7B), probably because of the
greater exposure of the tubulin-binding
site because of the truncation of the C ter-
minus in the former. This effect is specific
for CRMP5, since the presence of large
amounts of bovine serum albumin during
Figure 6. CRMP5 counteracts CRMP2 neurite outgrowth promotion in a culture of hippocampal neurons at DIV 6 by a tubulin-
basedmechanism.A, E18 hippocampal neuronswere cultured for 4 d, and then transfectedwith Lipofectamine and fixed after 2 d
before antibody labeling. Transfections were performed with EGFP, EGFP-CRMP5, or FLAG-CRMP2 constructs. CRMP5 expression
inhibits the length of shorter neurites (dendrites; white arrow), whereas the longest neurite (axon; white arrowhead) lengths are
comparable with control EGFP. Consistent with previous results (Fukata et al., 2002), the overexpression of CRMP2 alone induces
significant elongation of processes. B, Hippocampal neurons were stained with dendritic marker MAP2 (red) and axon marker
tau-1 (blue) antibodies to confirm that, at DIV 6, the shorter neurites are dendrites and the longest neurite is an axon. C, Quanti-
fication of process lengths. The length of the longest neurite (axon) and all remaining shorter neurites (dendrites) of an individual
neuron were measured within each treatment. Neurons expressing full-length CRMP5 (n
 42 neurons; gray bars) and CRMP5
C518 (n
 38 neurons; dotted bars) show axon lengths identical with the control EGFP (n
 55 neurons), whereas they present
4
shorter dendrite lengths. CRMP5C472 (hatched bars) has no
effect ondendrite length. As reportedpreviously (Fukata et al.,
2002), CRMP2 enhances axon and dendrite lengths (n
 63
neurons). In neurons coexpressing full-length CRMP5 or
CRMP5C518 and CRMP2 (n
 46 and 28 neurons, respec-
tively), both axon and dendrite lengths decrease to the level of
cells expressing CRMP5 alone, suggesting that CRMP5negates
the CRMP2 effect. In neurons coexpressing truncated CRMP5
472 and CRMP2 (n 
 60 neurons), axon and dendrite
lengths reach those of CRMP2-expressing cells, indicating that
when the tubulin-binding site is deleted, CRMP5 fails to coun-
teract the CRMP2 activity (**p  0.01; ***p  0.005). D,
Quantification of the number of dendrites. At DIV 6, neurons
expressing CRMP5 exhibit a dendrite number identical
with control EGFP, whereas neurons expressing CRMP2
show higher number of dendrite (*p 0.05). E, Quantifica-
tion of the number of secondary axons and the frequency of
axon branching. The second longest neurite exhibiting no less
than one-half the axon length (white bars) is considered
as a secondary axon. CRMP5-expressing neurons, like EFGP-
transfected neurons, do not exhibit secondary axon, whereas
CRMP2 induces secondary axons. CRMP5 has no significant ef-
fect on the frequency of axon branching (gray bars), whereas
CRMP2 increases axon branching. The cotransfection of both
CRMP5 and CRMP2 results with an intermediate value sug-
gests that CRMP5 does not act as a dominant signal (*p
0.05; **p 0.01; ***p 0.001). Error bars indicate SEM. F,
Double transfection was performed with FLAG-CRMP2 and
EGFP-CRMP5 or EGFP-CRMP5 472, EGFP-CRMP5 518.
Double-transfected cells were selected among yellow-colored
cells in the merge image. Neurons coexpressing both CRMP5
(full-length or C518) and CRMP2 present process lengths
comparable with CRMP5 but shorter axon and dendrites
lengths comparedwith CRMP2-expressing neurons.When the
tubulin-binding site on CRMP5 is deleted (C472), its coex-
pression with CRMP2 leads to cell morphologies similar to
CRMP2, suggesting that the dominant effect of CRMP5 de-
pends on the presence of the tubulin-binding site. Scale bars,
100m.
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the incubation did not influence the tubulin-CRMP2 interaction
(data not shown).However, even at high concentrations, CRMP5
loss-of-function mutant C472 lacking the tubulin-binding site
could not counteract CRMP2 binding, since CRMP2 still bound to
tubulin (Fig. 7B). These data suggest that direct tubulin binding to
CRMP5 impairs the binding of tubulin to CRMP2. Nonetheless,
as CRMP proteins can form homocomplex and heterocomplex
between isoforms (Wang and Strittmatter, 1997; Deo et al., 2004;
Stenmark et al., 2007), the hypothesis that a direct CRMP5 bind-
ing to CRMP2 may slow down its ability to process neurite out-
growth cannot be totally excluded. To check this hypothesis, we
performed in vitro binding assays, in the absence of tubulin,
using recombinant GST-CRMP2 and various concentrations
of either full-length, C521, or C472 forms of CRMP5. The
control GST did not bind to CRMP5. Different concentrations
of all CRMP5 isoforms, including C472, were pulled down by
GST-CRMP2 (Fig. 7C), indicating that these forms interacted
with CRMP2. Nevertheless, the fact that CRMP5 C472, which
did not counteract CRMP2 promotional activity still bound to
CRMP2, indicates that the direct CRMP5/CRMP2 interaction
does not correlate with CRMP5 inhibitory effect. Together, the
above data suggest that, although CRMP5/CRMP2 oligomeriza-
tion does occur, however only the direct CRMP5 binding to tu-
bulin by preventing tubulin/CRMP2 interaction can antagonize
CRMP2 promotional effect.
CRMP2 outgrowth promotion is enhanced in
CRMP5-deficient neurons
A few days after axon has began its formation and rapid growth,
remaining processes elongate and acquire the characteristic of
dendrite (Dotti et al., 1988). As significant dendrite elongation
begins between days 3 and 5, to assess the function of endogenous
CRMP5 on dendrite outgrowth, at an early stage of development,
we knocked down the CRMP5 expression in hippocampal neu-
rons, by siCRMP5 on day 1 after plating, and then neurons were
examined 2 d after transfection at DIV 3. First, the effect of
CRMP5 expression was examined at early stage of development
in hippocampal neurons from E18 mouse embryo transfected
with EGFP-CRMP5. Compared with control EGFP expression
(n
 52 neurons), the expression of EGFP-CRMP5 (n
 37 neu-
rons) significantly reduced the lengths (**p 0.01) and numbers
(***p  0.001) of neurites per cell considered as primary den-
drites. Then, we studied the consequence of CRMP5 depletion by
its knockdown with siCRMP5. The knockdown was confirmed
by immunoblot analysis (Fig. 8A). In CRMP5-depleted neurons
(n
 45), the length and number of primary dendrites were un-
ambiguously higher (**p  0.01) than the control SC neurons
(n 
 25), indicating that in vivo, CRMP5 exerted an inhibitory
effect on dendrite outgrowth and initiation at an early stage of the
development (Fig. 8A,B). A double staining of the neurons with
anti-tau1 and anti-MAP2 antibodies confirmed that the long
neurite was the axon and the other neurites were dendrites (Fig.
8D). The reexpression of CRMP5 in neurons treated with
siCRMP5 confirmed that the negative effect of CRMP5 was
rescued by the expression ofCRMP5 (supplemental Fig. S4, avail-
able at www.jneurosci.org as supplemental material). As ob-
served for neurons at DIV 6, CRMP5 overexpression, at DIV 3,
did not have any significant effect on axon length (Fig. 8B). How-
ever, endogenous depletion of CRMP5 slightly, but not signifi-
cantly, increased the axon length compared with SC-expressing
neurons (Fig. 8B). Because CRMP5 overexpression antagonized
the neurite outgrowth promotion induced by CRMP2 expres-
sion, we asked whether the knockdown of endogenous CRMP5
had an effect on the CRMP2 induced outgrowth. Remarkably, in
neurons knocked down for CRMP5 expression but overexpress-
ing the CRMP2 construct (n
 28 neurons), the length and num-
bers of primary dendrites were higher (**p  0.01) than in
neurons expressing CRMP2 and SC (n
 32 neurons), indicating
an antagonizing effect of endogenous CRMP5 at the dendritic
level (Fig. 8C,E). The negative effect of CRMP5 on dendrite
growth and formation was rescued by restoring CRMP5 expres-
sion (Fig. 8E). These results strongly support the inhibitory effect
of endogenous CRMP5 on both the outgrowth and formation of
Figure 7. CRMP5 antagonizes the tubulin–CRMP2 interaction. A, SDS-PAGE showing each
His-CRMP5 truncated protein and GST-CRMP2 protein confirms the correct mass for recombi-
nant proteins. The bars on the left indicate the positions ofmolecularmarker bands.B, Purified
tubulin incubatedwith GST-CRMP2 recombinant protein or GST, pulled down in the presence of
different concentrations (0–1.3 M) of either full-length or truncated CRMP5 (C521 or
C472), shown in A. Western blots of the pellets, probed with an anti--subunit antibody,
shows that CRMP2precipitates the tubulin, in theabsenceor thepresenceof lowconcentrations
(0.5M) of all forms of CRMP5. Higher concentrations of full-length orC521 CRMP5 de-
crease or prevent the tubulin pull down by GST-CRMP2, whereas CRMP5 C472 lacking the
tubulin-binding site did not prevent it. Tubulin is present in the supernatant fraction of all
assays. Control GST, incubated with the highest concentration of all CRMP5 forms, failed to
precipitate the tubulin. C, GST-CRMP2 or GST was pulled down in the absence or presence of
different concentrations (0–1.3 M) of either full-length, or truncated His-tagged CRMP5
(C521 orC472), shown in A. Western blots of the pellets, probed with an anti-His antibody
(CRMP5 detection), shows that CRMP2 precipitates all different forms of CRMP5. Control GST
failed to precipitate different forms of CRMP5.
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Figure8. Effect of CRMP5depletionondendrite andaxonoutgrowth in culturedhippocampal neurons atDIV3.A, E18hippocampal neuronswere cultured for 1d, and then transfectedwith EGFP
or EGFP-CRMP5 or cotransfected with EGFP and SC or siCRMP5. The knockdown of CRMP5 expression by siCRMP5 in cultured neurons is shown byWestern blots probed with anti-CRMP5 antibody.
Overexpression of EGFP-CRMP5 at DIV 3 inhibits neurite growth (arrow), whereas the length of the longest neurite, the axon (arrowhead) is comparable with the control EGFP. CRMP5 depletion
considerably enhances the length and the number of short neurites, without effect on axon length, whereas the control neurons transfected with SC show phenotypes comparable with EGFP-
transfected neurons. The bottom panels show dendrites and soma under high magnification. Scale bars, 100m. B, Quantification of process lengths and numbers shown in A. At DIV 3, neurons
expressingCRMP5 (n
37) showaxonal lengths identicalwith the control EGFP (n
52neurons),whereasneuronsdepletedof CRMP5 (n
45) showavery slight increase in axon length (redbars)
compared with SC-treated neurons (n
 62). However, neurite lengths (yellow bars) and numbers (green bars) are decreased with CRMP5 expression, but increased with CRMP5 depletion when
comparedwith SC (**p 0.01; ***p 0.001). C, CRMP2 activity is enhanced by CRMP5 depletion. E18 hippocampal neurons were cultured for 1 d, and then cotransfectedwith FLAG-CRMP2 plus
siCRMP5or SC, as control, for 2 dbefore immunostainingwith anti-FLAGantibody. Depletion of CRMP5allows anenhanced effect of CRMP2ondendrite length andnumber aswell as on axongrowth
and branching, indicating that endogenous CRMP5 restricts CRMP2 functions. Dendrites are shown under high magnification in bottom right panels. Scale bars, 100m. D, Immunostaining of
cultured hippocampal neurons at DIV 3with dendriticmarkerMAP2 and axonmarker tau-1 antibodies. E, Quantification of process lengths and numbers shown in C. At DIV 3, neurons cotransfected
with FLAG-CRMP2 and siCRMP5 (n
 28 neurons) show an increase in the promotional activity of CRMP2 on neurite length (yellow bars) and numbers (green bars) (Figure legend continues.)
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primary dendrite counterbalancing the outgrowth promotion
activity of CRMP2. Compared with cultured hippocampal neu-
rons at DIV 3, CRMP2 expression in the presence of SC (n
 40
neurons) increased by 1.3-fold the axon length. Interestingly,
knockdown of CRMP5 in hippocampal neurons expressing
CRMP2 (n 
 37 neurons) increased even more (1.5-fold; ***p 
0.005) axon length and enhanced (3-fold) the number of multiple
secondary axons (**p0.01),withneuronspresenting complicated
multibranched axon trees (Fig. 8C,F). The overexpression of
CRMP5 in CRMP2 plus siCRMP5-transfected neurons brought
down the axon length to that of the control (Fig. 8F), strengthening
the argument that endogenous CRMP5 controlled the axon growth
effectofCRMP2.However, it shouldbenoticed thatCRMP5didnot
exert an inhibitory effect on axon growth since axon length reached
the level of control. Together, our data clearly confirmed the role of
endogenous CRMP5 at early developmental stages, in preventing
dendrite growth and formation and in the regulation of CRMP2
promotional growth.
CRMP5 expression is not persistent in hippocampal neurons
Because CRMP5 inhibited dendrite outgrowth and modulated
CRMP2 activity, we tested whether these effects were correlated
with the CRMP5 level of expression in dendrites by studying the
spatiotemporal distribution of CRMP5. The subcellular distribu-
tion of CRMP5 had previously been studied, in cultures of hip-
pocampal neurons byHotta et al. (2005), but only at DIV 1 and 7,
with a focus on the growth cone accumulation of CRMP5. There-
fore, we studied the endogenous expression of CRMP5, in cul-
tured hippocampal neurons at DIV 1–6, and compared it with
endogenous CRMP2 expression and MAP2 by double staining
using different combination of anti-CRMP5, anti-CRMP2, and
anti-MAP2 antibodies (Fig. 9A,B). Green fluorescence intensi-
ties representing CRMP5 expression, determined from selected
neurons, were shown as a three-dimensional intensity projection
(Fig. 9A, left panels). Fluorescence intensities, indicative of
CRMP5, CRMP2, and MAP2 expression, were determined from
defined region on dendrites and axon using imaging software
(ImageJ) and graphed as fluorescence values (Fig. 9D). The pre-
cise length of dendrites and axon at each day of culture was de-
termined, specifically in the absence of CRMP2 and CRMP5
expression, using CellTracker Green, CMFDA, 5-chloromethyl
fluorescein diacetate (supplemental Fig. S5, available at www.
jneurosci.org as supplemental material). Minor CRMP5 and
MAP2 expressions could be detected only in soma after 1 and 2 d
of culture (Fig. 9A), whereas CRMP2 expression in neurites was
clearly detected since day 2 of culture (38 12 AU) (Fig. 9B,D).
At DIV 3, one of the immature neurite, showing high CRMP2
expression (46.8 9.6 AU) elongated rising 332 m (50 m)
in length to become the future axon (Fig. 9B,D), at the same time
a strong expression of endogenous CRMP5 was detected in the
soma and primary dendrites (37.1 6.9 AU) presenting a colo-
calization with MAP2 and CRMP2 (Fig. 9A,B). In contrast to
axon, the dendrite length did not change at DIV 3 (30 6.7 m
instead of 28  6.5 m at DIV 2) (Fig. 9D). Accordingly, the
MAP2 expression in dendrite, considered as an indication of
dendrite outgrowth, remained low (Fig. 9D, middle panel). This
suggested that high CRMP5 expression during axonogenesis
maintained the primary dendrites inhibited. CRMP5 was also
distributed in the axon, but to a lesser extent (10.5  2.6 AU)
(Fig. 9D), whereas CRMP2 expression was almost equivalent in
axon and primary dendrites. During following stages of neuronal
development, corresponding to dendrite outgrowth (Fig. 9D, top
panel), a decrease in CRMP5 expression was observed in den-
drites (17.7 4.6AU) atDIV 4, followed by a very low expression
level at DIV 5 (2.1  1 AU), at which an absence of CRMP5
staining was noticed in dendrites (Fig. 9A,B; supplemental Fig.
S5, available at www.jneurosci.org as supplemental material),
whereas the CRMP2 expression remained almost constant (Fig.
9D, bottom panel). On the opposite, a strong labeling was ob-
served with MAP2, indicating the dendrite outgrowth, whose
length reached at DIV 5 50 10 m (Fig. 9D, top panel), which
perfectly matched with that previously reported (Dotti et al.,
1988). It should be noted that MAP2 expression increased con-
sistently in dendrites fromDIV 1 to 6 (from 1.6 1.3 to 37.5 6
AU) (Fig. 9D). In accordance with a previous report (Hotta et al.,
2005), at DIV 6, a wide redistribution of CRMP5 was observed
within hippocampal neurons, including soma, dendrites, and
axon. Although CRMP5 expression was very low in axon at the
beginning, it became very high (38.7 10.7 AU) at this stage of
development (Fig. 9A,D), suggesting a role for CRMP5 in con-
trolling the axon elongation at later stages of development. At
DIV 6, CRMP5 was also observed de novo, at the dendritic level,
however, to a lesser extent than at DIV 3 (14.1  3.3 AU) (Fig.
9D), whereas CRMP2 expression in dendrites and axon remained
at high level, suggesting that, in the absence of CRMP5, CRMP2
promoted dendrite outgrowth. The expression level of both
CRMP5 and CRMP2 in hippocampal neurons was further exam-
ined byWestern blot analysis of a lysate of neurons from each day
of culture. Figure 9C showed that the band migrating at 66 kDa
recognized by anti-CRMP5 antibody presented high intensity at
DIV 3, its intensity progressively decreased to reach a very low
level at DIV 5, but at DIV 6 this band showed again very high
intensity. The higher intensity at DIV 6 compared with DIV 3
might be explained by the fact that, as mentioned above, the
CRMP5 expression was increased at the axon level at DIV 6. The
band recognized by anti-CRMP2 antibody, although exhibiting
low intensity at DIV 1–2, showed similar high intensity fromDIV
3 onward, with the highest intensity reached at DIV 5 at which
multiple isoforms of CRMP2, previously described (Rogemond
et al., 2008), could be visualized (Fig. 9C). These results, in
perfect agreement with the above data on fluorescent quanti-
fication of CRMP5 and CRMP2 expression, demonstrate the
transient expression of CRMP5. Together, our data demon-
strated that a correlation might exist between CRMP5 expres-
sion and its inhibitory effect on dendrite growth during
axonogenesis; subsequently, its absence of expression at DIV 5
of neuronal development allowed dendrites to grow, suggest-
ing a role for CRMP5 in maintaining them in a quiescent state
at early stages of development, thus regulating the establish-
ment of neuronal polarity.
4
(Figure legend continued.) when compared with neurons cotransfected with CRMP2 and SC
(n
 31 neurons). However, when CRMP5 is overexpressed in the above cotransfected neurons
(n
 15), the CRMP2 effect is completely abolished, leading to an inhibition of neurite growth
and number similar that of CRMP5 expression indicated in B. F, Quantification of axon length
and multiple axon, shown in C. CRMP5 knockdown in cultured neurons at DIV 3 expressing
FLAG-CRMP2 amplifies the CRMP2 effect on axon growth when compared with control SC,
whereas CRMP5 overexpression abolishes this effect (**p 0.01). In addition, as previously
described (Fukata et al., 2002), we observed that CRMP2 induces a multiple axon formation
(n 
 40 neurons), but the knockdown of CRMP5 (n 
 37 neurons) leads to a significant
increase (3-fold; **p 0.01) in neurons bearing multiple axons, indicating that endogenous
CRMP5may exert an effect on delimiting CRMP2 promotion of axon growth. Data are themean
values of three individual experiments. Error bars indicate SEM.
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Figure 9. Transient spatiotemporal expression of CRMP5 compared with CRMP2 expression in cultured hippocampal neurons. A, E18 hippocampal neurons were cultured without any transfec-
tion, from DIV 1 to 6, and then fixed and immunostained with anti-CRMP5 (green) and anti-MAP2 (red) to follow the distribution of endogenous CRMP5 and the dendritic marker, respectively.
Representative images of neurons are presented for each DIV. The images in left panels represent three-dimensional intensity projections of CRMP5 at the indicated time. At DIV 1 and 2, CRMP5 and
MAP2 staining are restricted to the soma (white arrowhead). At DIV 3, CRMP5expression is clearly detected in dendrites, axon, and soma, themerge image shows a clear colocalization of CRMP5and
MAP2 in dendrites. This colocalization is no longer observed at DIV 5, wheremerge image shows longer dendrites stained redwith anti-MAP2. The inset is amagnification of soma and dendrites. At
DIV 6, CRMP5 staining is predominantly observed at the axon level, where a clear green staining can be observed at the merge image. CRMP5 is de novo expressed in dendrites. Scale bars, 50m.
B, E18 hippocampal neurons were cultured as in A and immunostained with anti-CRMP5 (green) and anti-CRMP2 (red) antibodies. Representative images of neurons are presented for each day as
merge images showing CRMP5 and CRMP2 double staining. The inset shows the CRMP2 immunolabeling in red. At DIV 1 and 2, CRMP5 and CRMP2 staining overlapped at the soma. In contrast to
CRMP5, a CRMP2 expression is detected at DIV 2 in neurites, which are clearly stained red in themerge image; note the presence of the longer neurite, which will become the future axon. From DIV
3 to 6, high CRMP2 staining is persistently and clearly observed in dendrites, axon, and soma. As observed in A, CRMP5 shows a peak of expression at DIV 3 and DIV 6, where it is unambiguously
colocalizedwith CRMP2 in axon and dendrites stained yellow. The decrease of CRMP5 expression is confirmed by clear red staining of axon and dendriteswith anti-CRMP2 at DIV 4 and 5, as observed
inmerged images. Scale bars, 50m. C, Expression of CRMP5 and CRMP2 in a culture of hippocampal neurons byWestern blot analysis on DIV 1 through DIV 6. E18 hippocampal neurons in culture
were collected each day. After lysis, the cells were subjected to SDS-PAGE andWestern blot probed for CRMP5 and CRMP2 immunoreactivity. Antibody to GAPDH is used as a control of the amount
of protein loaded. The total expression of CRMP5 protein in neurons shows unambiguously two high-intensity bands at DIV 3 and DIV 6with a decrease in intensity in DIV 4 and 5. However, the total
CRMP2 expression is similarly high from DIV 3 through DIV 6. Note the presence of multiple isoforms of CRMP2 at DIV 5 with slightly higher intensity. D, Quantification of CRMP5 and CRMP2
fluorescence indendrites andaxon in relation to their lengths. The toppanel shows the lengthof extensions fromhippocampalneurons culturedas inAatDIV1 toDIV6. Theprecise lengthofneurites,
axon, or dendrites is determined on hippocampal culture stainedwith CMFDA (supplemental data 4, available atwww.jneurosci.org as supplementalmaterial). Themiddle and bottompanels show
the fluorescence intensity fromA andB determined after conversion of each fluorescent image into a gray scale. Quantitativemeasurements are obtained by averaging the intensity of fluorescence
within a box size of 40 40 pixels drawn on different regions of the dendrites and axon (n
 10 measurement boxes within each neuron), using ImageJ software. (Figure legend continues.)
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Discussion
In this study, we provide evidence for a novel role of CRMP5 in
inhibiting neurite outgrowth through binding to tubulin and
MAP2 during brain development. Overexpression of CRMP2
was reported to promote neurite elongation and axon induction
(Arimura andKaibuchi, 2007), whereas CRMP3was described as
enhancing dendrite branching inmouse hippocampus (Quach et
al., 2008). A change in cell shape after CRMP5 overexpression has
previously been reported (Suzuki et al., 2003). Although CRMP5
is distributed throughout axon and dendrites (Bretin et al., 2005;
Hotta et al., 2005), growth inhibition is observed at the dendritic
level, but not in the axon in hippocampal neurons. CRMP5 also
inhibits dendrite initiation, although this inhibition occurs only
at an early developmental stage (stage 3) concomitant with its
strong expression in dendrites. Knockdownof CRMP5unambig-
uously confirms its inhibitory function. Nevertheless, CRMP5
deficiency results in greater neurite numbers and lengths in N1E-
115 cells than in neurons. In neurons, other negative signaling
molecules may partially compensate for CRMP5 function.
CRMP associations with tubulin have been reported for
CRMP1-4 (Fukata et al., 2002), whereas a CRMP5–tubulin inter-
action has not yet been identified. We demonstrate that CRMP5
interacts with tubulin and MAP2 in mouse brain cortex during
development, forming a ternary complex, within which CRMP5
shows direct binding to - and -tubulin. The colocalization of
CRMP5 and tubulin at the cytosolic level supported their inter-
action. The tubulin-binding domain is mapped to a C-terminal
fragment of CRMP5 (residues 475-522). The C-terminal part of
CRMP5 fell into the category of “intrinsically unstructured pro-
teins,” characterized by a flexible and unfolded state, favoring
interactions with other partners. Consequently, the tubulin-
interacting domain, located within this region, would be easily
available for binding to tubulin. Previous reports differ on the
tubulin-binding properties of CRMP2. A central domain (resi-
dues 323-381) was reported to be involved in CRMP2 activity on
microtubule assembly (Fukata et al., 2002). As this site is located
in a hidden region in the x-ray structure (Stenmark et al., 2007),
CRMP2 may have to undergo some conformational change to
expose it. In contrast, a recent study identified CRMP2 residues
480-509 as being responsible for such activity (Chae et al., 2009).
The latter site resembles the identified CRMP5 tubulin-binding
site. However, despite the strong sequence homology between
CRMPs and the surface exposure of both sites, they show a low
sequence homology.
Distinct pathways are involved in different CRMP-mediated
neurite outgrowth functions through actin-binding (Alabed et
al., 2007) or tubulin-binding mechanisms (Fukata et al., 2002).
We demonstrate that overexpression of CRMP5 bearing the
tubulin-binding site inhibits neurite outgrowth, whereas the ex-
pression of CRMP5C472, devoid of tubulin-binding site, failed
to inhibit it. Similarly, CRMP5 tubulin-binding capacity is required
for inhibition of dendrite outgrowth in neurons.Moreover, we find
that recombinant CRMP5 inhibits tubulin polymerization in an
in vitro microtubule polymerization assay, whereas CRMP5
C472 does not. Similar mechanism inhibits neurite forma-
tion, since CRMP5 C472 expression failed to reduce the
number of neurites, whereas different forms of CRMP5 bear-
ing the tubulin-binding site did. The inhibition is more pro-
nounced for C518 and N244 than for full-length forms. This
may be explained by a greater accessibility of the tubulin-binding
site in the C-terminally deleted form and the induction of a con-
formational change in the N-terminally deleted form leading to a
better exposure of this site.
MAP2 plays an essential role inmodulating the growth (Brugg
and Matus 1988) and the initiation of neuronal processes by
maintaining the linkage or mediating cross talk between micro-
tubules and other cytoskeletal elements. The presence of MAP2
denotes a difference in the way that tubulin interacts with
CRMP5 and CRMP2, since MAP2 interactions with other
CRMPs were not found in previous reports (Fukata et al., 2002).
NotwithstandingwhetherMAP2 binds toCRMP5 through direct
interaction or indirectly via tubulin, its presence within the com-
plex implies that it is a determinant factor in the inhibitory role of
CRMP5 notably at the dendritic level. Several observations sup-
port this theory. First, in vivo, CRMP5 forms a complex with
MAP2 and tubulin. Second, consistent with our observations, a
colocalization of CRMP5 and MAP2 in dendrites was previously
reported (Bretin et al., 2005). Third, in axon, devoid of MAP2,
CRMP5 does not exert inhibitory activity. Therefore, we can as-
sume that by forming a complex with tubulin heterodimers and
MAP2,CRMP5 locks themicrotubular structure andprevents addi-
tional microtubule polymerization, thereby inhibiting neurite out-
growth and formation.
Antagonistic roles of CRMP5 and CRMP2
The study of the combinatorial functions of both CRMP5 and
CRMP2 led to the important finding that the neurite outgrowth-
promoting function of CRMP2 is totally abrogated by neurite
outgrowth inhibition induced by CRMP5, indicating that
CRMP5 acts as the dominant signal. In cultured hippocampal
neurons, dendrite elongation and initiation induced by CRMP2
expression is considerably enhanced by a CRMP5 deficiency,
strengthening the fact that, in vivo, endogenous CRMP5 restricts
CRMP2 function. CRMP2 expression results in axon induction and
the formation of multiple axons, as reported previously (Inagaki et
al., 2001). Abrogation of the CRMP2 outgrowth promotion is ob-
served not only at the dendritic level but also at that of the axon.
Nevertheless,CRMP5expressiondoesnotexert inhibitoryactivity at
the axon level since the axon length never falls below the level of
controls, but it abolishes CRMP2 induction of axon growth. A
CRMP5 deficiency in neurons results also in increased CRMP2-
induced axon elongation and the number of multiple axons, sug-
gesting that, in vivo, CRMP5 may modulate CRMP2 induction of
both axon growth andmultiple axon formation.
Different mechanisms may govern the antagonizing function
of CRMP5. First, by binding to CRMP2, CRMP5may counteract
its ability to process neurite outgrowths. However, despite the
direct interaction between CRMP5 and CRMP2 observed in this
study and reported by others (Fukada et al., 2000), the fact that
the loss-of-function CRMP5 C472 still binds to CRMP2 with-
4
(Figure legend continued.) Average fluorescence intensities obtained from these boxes in a
number of neurons are plotted in arbitrary units (a.u.). On the dendritic level, CRMP5 show very
lowexpression atDIV 1 and2 (n
22and19neurons, respectively), andCRMP2exhibits higher
expression at DIV 1 and 2 (n
 11 and 13 neurons, respectively). A peak of CRMP5 expression at
DIV 3 (n
 29 neurons) can be observed, concomitant with axonal growth, whereas CRMP2
expression does not change (n
 16 neurons). Compared with DIV 3, CRMP5 expression de-
creases by 2.2-fold at DIV 4 (n
 26 neurons; p 0.05) and 18-fold at DIV 5 (n
 22 neurons;
p 0.0005), where dendrites begin their growth and show high MAP2 expression. On the
opposite, CRMP2 expression slightly increases on DIV 4 and 5 (n
 13 neurons). CRMP5 expres-
sion increases by sixfold at DIV 6 compared with DIV 5 (n
 22 neurons; p 0.001), whereas
CRMP2 expression does not significantly change (n
 13 neurons). On the axon level, CRMP5
expression decreases fromDIV 3 to DIV 5, followed by significant reexpression at DIV 6 (3.3-fold
compared with DIV 3; p 0.01). CRMP2 expression is persistent from DIV 2 to DIV 6, with a
slight increase of expression at DIV 5. Error bars indicate SEM.
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out influencing its activity does not support this interpretation.
Second, CRMP5 and CRMP2 bind competitively to tubulin. In-
deed, in contrast to the full-length and CRMP5 C518 bearing
the tubulin-binding site, the CRMP5 C472 failed to abrogate
the CRMP2 promotion of axon and dendrite outgrowth in hip-
pocampal neurons, suggesting that CRMP5 antagonistic activity
is tubulin-binding dependent. In addition, only recombinant
CRMP5 bearing the tubulin-binding site, but not CRMP5
C472, can disrupt the in vitro binding of CRMP2 to tubulin. By
binding to tubulin heterodimers, CRMP2 transports them, via
kinesin-1 motor proteins, to the plus-ends of microtubules to
promote neurite extension (Kimura et al., 2005). Thus, by bind-
ing to microtubules, CRMP5 impairs CRMP2 transport of tubu-
lin, preventing it to promotemicrotubule assembly, which causes
the modification of the microtubule networks.
CRMP5 in neuronal polarity
As CRMP2 plays a role in the establishment and maintenance of
neuronal polarity by inducing axonal growth (Yoshimura et al.,
2005), endogenous CRMP5, by restricting CRMP2 activity, may
intervene in the regulation of neuronal polarity. In this study,
using different approaches, we find that the CRMP2 expression is
almost constant during neuronal development, whereas CRMP5
presents two peaks of expression at DIV 3 and 6. Neuronal polar-
ization occurs from stage 2 to 3, at which one of the immature
neurite begins to extend rapidly and becomes axon. Other neu-
rites remain quiescent for a few days until the axon begins to
growth, and then they elongate and acquire, at stage 4 (DIV 5),
the characteristics of dendrites (Dotti et al., 1988). To date, it is
not known why neurites other than the axon remain quiescent.
Here, several lines of inquiry have helped to elucidate this point.
First, we find that strong CRMP5 expression in dendrites occurs
at DIV 3, corresponding to axon growth and quiescent neurite.
Second, CRMP5 expression progressively diminishes and almost
stops at DIV 5, when dendrites begin to extend. Third, CRMP5
acts as an inhibitor of dendrite elongation and formation with no
effect on axon growth. Fourth, CRMP5 restricts the CRMP2
outgrowth promotional function. Considering the continuous
expression of CRMP2, it can be assumed that CRMP5, by coun-
teracting CRMP2, maintains neurites in a quiescent state at the
early stage of the development, allowing the axon to continue its
outgrowth, whereas its lack of expression thereafter allows den-
drites to elongate and to reach their mature state, probably be-
cause of the CRMP2-induced promotional outgrowth. A slight
CRMP5 reexpression can be observed in dendrites, at a later stage
of development (DIV 6), which may help control mature den-
drite length. This is consistent with our previous observations
that, at the postnatal stage, CRMP5 is present in the external
granular layer of cerebellum (Ricard et al., 2001) and CRMP5 is
expressed in soma and dendrites of adult brain (Bretin et al.,
2005). In parallel, high CRMP5 expression in the axon, at a late
developmental stage, may constrain CRMP2-induced growth,
delimiting axonal length. Whereas many intracellular and extra-
cellularmolecules seem to determine neuronal polarity (Arimura
and Kaibuchi, 2007), our observations suggest that CRMP5 can
be considered as one of themolecules involved in regulating neu-
ronal polarity.
In conclusion, the modulation of CRMP5 expression in neu-
rons is a critical factor in regulating neurite outgrowth and neu-
ronal polarity, ensuring the establishment of normal neuronal
communication during brain development.
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